ABCL - AbCellera partners with RQ Bio on infectious disease treatments

2023-03-22 10:06:44 ET

• AbCellera Biologics ( NASDAQ: ABCL ) will work with RQ Bio to dentify optimal clinical candidates for up to three infectious disease targets chosen by the latter.
• The disease areas will include influenza and cytomegalovirus (CMV).
• Terms call for privately held RQ Bio to develop and commercialize antibodies resulting from the partnership. AbCellera ( ABCL ) will receive research payments and is eligible to receive milestone payments and royalties on net sales of products developed as part of the collaboration.
• Read why Seeking Alpha contributor Confoundedinterest reiterated their strong buy rating .

For further details see: